INT9349

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1992
Last Reported 2010
Negated 4
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 12.77
Pain Relevance 4.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (BBS2) cytoplasm (BBS2)
Anatomy Link Frequency
respiratory 3
bar 1
chest 1
lung 1
BBS2 (Homo sapiens)
Pain Link Frequency Relevance Heat
beta blocker 856 100.00 Very High Very High Very High
qutenza 7 97.36 Very High Very High Very High
agonist 70 91.92 High High
Angina 22 82.52 Quite High
unmyelinated 1 72.08 Quite High
ischemia 2 66.36 Quite High
tolerance 10 36.80 Quite Low
Calcium channel 10 5.00 Very Low Very Low Very Low
Nicotine 6 5.00 Very Low Very Low Very Low
Versed 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Disease 619 100.00 Very High Very High Very High
Bardet-biedl Syndrome 7 100.00 Very High Very High Very High
Nicotine Addiction 204 99.84 Very High Very High Very High
Disease 61 98.64 Very High Very High Very High
Acute Coronary Syndrome 30 98.48 Very High Very High Very High
Myocardial Infarction 180 98.28 Very High Very High Very High
Coronary Artery Disease 60 96.52 Very High Very High Very High
Phobia 30 95.76 Very High Very High Very High
Adverse Drug Reaction 30 95.08 Very High Very High Very High
Bronchospasm 50 94.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This demonstrated that cardioselective BBs produced no significant change in FEV1 or respiratory symptoms compared to placebo and did not significantly affect the FEV1 treatment response to ?
Gene_expression (cardioselective) of BBs in respiratory associated with beta blocker
1) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 0.52 Pain Relevance 0.19
A diagnosis of “COPD” was the most common cause for withholding BBs and only 62% of patients with COPD have been reviewed by a chest physician or had a previous pulmonary function test.
Gene_expression (diagnosis) of BBs in chest associated with pulmonary disease and beta blocker
2) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.12 Pain Relevance 0.43
The conclusion was again that cardioselective BBs given to COPD patients do not produce a significant reduction in airway function or an increase in the incidence of COPD exacerbations.
Neg (not) Gene_expression (produce) of BBs associated with pulmonary disease and beta blocker
3) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 0.93 Pain Relevance 0.29
This demonstrated that cardioselective BBs produced no significant change in FEV1 or respiratory symptoms compared to placebo and did not significantly affect the FEV1 treatment response to ?
Neg (no) Gene_expression (produced) of BBs in respiratory associated with beta blocker
4) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 0.57 Pain Relevance 0.19
The conclusion was that cardioselective BBs do not produce clinically significant adverse respiratory effects in patients with mild to moderate reactive airway disease, and that they should not be withheld from these patients.
Neg (not) Gene_expression (produce) of BBs in respiratory associated with beta blocker and disease
5) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 0.69 Pain Relevance 0.31
Of these COPD patients, only 16% were prescribed BBs and many patients with a diagnosis of COPD have no objective evidence to support this diagnosis.
Gene_expression (prescribed) of BBs associated with pulmonary disease and beta blocker
6) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.24 Pain Relevance 0.44
However, despite the clear evidence of BBs effectiveness, there is a general reluctance to use them in patients with COPD due to a perceived contraindication and fear of inducing adverse reactions and bronchspasm (Kennedy and Rosenson 1995; Viskin and Barron 1996; Gottlieb et al 1998; Chafin et al 1999).
Gene_expression (effectiveness) of BBs associated with adverse drug reaction, phobia, pulmonary disease and beta blocker
7) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.15 Pain Relevance 0.28
BBs are often avoided in these patients (Kennedy and Rosenson 1995; Viskin and Barron 1996; Gottlieb et al 1998; Chafin et al 1999) because of fear of bronchospasm and possible adverse reactions, despite the known cardiovascular mortality and morbidity benefit (Frishman et al 1984; The IPPPSH Collaborative Group 1985; Wadworth et al 1991; Stienbeck et al 1992; Mangono et al 1996; Doughty et al 1997, JNC VI 1997; Lechat et al 1998; Freemantle et al 1999; Heidenreich et al 1999; Polderman et al 1999).
Gene_expression (avoided) of BBs associated with adverse drug reaction, phobia, beta blocker and bronchospasm
8) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.44 Pain Relevance 0.47
The cumulative evidence from trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients with reactive airway disease or COPD (Salpeter et al 2001, 2002a, 2002b, 2003).
Neg (not) Gene_expression (withheld) of BBs associated with pulmonary disease, beta blocker and disease
9) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.14 Pain Relevance 0.29
Finally, although we believe physicians should feel more comfortable prescribing cardioselective BBs to COPD patients, we can not make a generalised recommendation that BBs can be used in all COPD patients.
Gene_expression (used) of BBs associated with pulmonary disease and beta blocker
10) Confidence 0.49 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 0.59 Pain Relevance 0.48
The results indicated that BBS suppressed bar pressing, regardless of whether animals were pretreated with capsaicin or control vehicle.
Gene_expression (suppressed) of BBS in bar associated with qutenza and bardet-biedl syndrome
11) Confidence 0.27 Published 1992 Journal Peptides Section Abstract Doc Link 1409012 Disease Relevance 0.59 Pain Relevance 0.53
Of the 4900 inpatients, 3854 (78.7%) were treated by at least one of BBs, ACE/ARBs and/or statins, whilst no reimbursed prescriptions were found in the Estonian Health Insurance Fund database for 1046 (21.3%) patients during the 365 days after the index episode.
Gene_expression (one) of BBs associated with beta blocker
12) Confidence 0.13 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2911401 Disease Relevance 0.06 Pain Relevance 0.12
This list was then used to identify all prescriptions of BBs, ACE/ARBs and statins reimbursed to these AMI patients during a 12 month period (365 days) after the index episode.
Gene_expression (prescriptions) of BBs associated with beta blocker and myocardial infarction
13) Confidence 0.13 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2911401 Disease Relevance 0.58 Pain Relevance 0.19
Transcript profiling in BBs
Gene_expression (profiling) of BBs
14) Confidence 0.05 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.84 Pain Relevance 0
The expression of AHR, LXR, PXR and GR was not different in BBs of both study groups.
Gene_expression (expression) of BBs
15) Confidence 0.05 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.59 Pain Relevance 0
In the present study, we observed reduced expression of CYP2J2 in BBs of smokers, whereas CYP2C9 was significantly induced in this lung compartment.
Gene_expression (expression) of BBs in lung associated with nicotine addiction
16) Confidence 0.05 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.72 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox